Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Receptor tyrosine kinases (RTKs) are crucial in cell signaling and cancer therapy targets.
• Current c-kit inhibitors fail against the common Asp816Val mutation in malignant cancers.
• The ellipticine pharmacophore has shown potential for inhibiting mutant c-kit.

Purpose of the Study:

• To investigate the binding of ellipticine derivatives to mutant c-kit using advanced simulations.
• To understand the molecular interactions and binding modes of these inhibitors.
• To guide the design of novel inhibitors for c-kit-driven cancers.

Main Methods:

• High-level molecular simulation techniques were employed.
• Computational analysis of ellipticine derivative binding to c-kit was performed.
• Protonation states and stabilizing interactions were examined.

Main Results:

• Ellipticine derivatives exhibit a strong preference for protonation when bound to c-kit.
• Protonated ellipticine stabilizes interactions with protein residues coordinating ADP.Mg(2+).
• The binding mode resembles the native nucleotide complex, explaining experimental data.

Conclusions:

• Ellipticine-based inhibitors can effectively target mutant c-kit.
• Protonation is key to stabilizing inhibitor binding.
• Functionalization at C4/C5 positions is a promising strategy for developing new c-kit inhibitors.